Life Sciences

FDA warns Victory Pharma for misleading sales aid

Pharma Compliance Alert, December 24, 2008

A Victory Pharma sales aid minimizes risks, presents misleading safety information, and omits important risk information associated with the use of Xodol, according to an FDA warning letter.

According to the FDA, the sales aid also suggests that Xodol is safer and effective for use under broader conditions than has been demonstrated by substantial evidence or substantial clinical experience.

Comments

0 comments on “FDA warns Victory Pharma for misleading sales aid

 

    ePharm5 InDepth
  • ePharm5 InDepth

    EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

  • Medical Environment Update

    A subscription to Medical Environment Update pays for itself by saving you time sorting through complex regulations and...

  • Bloodborne Pathogens Training Video

    Meets OSHA requirements for training employees on the bloodborne pathogens standard!

  • Healthcare Marketing Advisor

    Healthcare Marketing Advisor provides concise, time-saving strategies for branding, promoting, and advertising your...

  • Needlestick Prevention Training Video

    Highlighting the five most frequent needlestick scenarios, this training video instructs frontline healthcare staff on on...

Most Popular